for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang Medicine Co., Ltd.

600216.SS

Latest Trade

13.29CNY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

8.25

 - 

14.03

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
13.29
Open
--
Volume
--
3M AVG Volume
498.32
Today's High
--
Today's Low
--
52 Week High
14.03
52 Week Low
8.25
Shares Out (MIL)
965.13
Market Cap (MIL)
12,826.55
Forward P/E
21.26
Dividend (Yield %)
1.13

Latest Developments

More

Zhejiang Medicine's 9-Month Net Profit Down 30.0% Y/Y

Zhejiang Medicine's Net Profit Down In Q1, Up In 2018 From Year Earlier

Zhejiang Medicine Plans Share Buyback Worth 50-150 Million Yuan Within Six Months

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zhejiang Medicine Co., Ltd.

Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.

Industry

Major Drugs

Contact Info

No. 58 Changhe Road, Binhai New City

+86.575.85211969

http://www.china-zmc.com

Executive Leadership

Chunbo Li

Chairman of the Board

Dingkuan Chen

Deputy General Manager

Yong Hui Lu

Deputy General Manager

Wenxin Ma

Deputy General Manager

Dingfeng Zhang

Deputy General Manager

Key Stats

1.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

5.7K

2018

6.9K

2019(E)

7.7K
EPS (CNY)

2017

0.270

2018

0.380

2019(E)

0.625
Price To Earnings (TTM)
58.95
Price To Sales (TTM)
1.81
Price To Book (MRQ)
1.64
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.06
LT Debt To Equity (MRQ)
0.75
Return on Investment (TTM)
2.20
Return on Equity (TTM)
1.69

Latest News

Latest News

BRIEF-Zhejiang Medicine's 2017 Net Profit Down, Q1 Net Profit Up

* SAYS 2017 NET PROFIT DOWN 43.8 PERCENT Y/Y AT 253.1 MILLION YUAN ($40.13 million)

BRIEF-Zhejiang Medicine 's 2017 Preliminary Net Profit Down, But Sees Q1 Net Profit Surging

* SAYS ITS PRELIMINARY 2017 NET PROFIT DOWN 41.52 PERCENT Y/Y AT 263.2 MILLION YUAN ($41.62 million)

BRIEF-Zhejiang Medicine unit receives Canada GMP certificate

* Says its unit receives Canada GMP certificate for vancomycin hydrochloride and related APIs

BRIEF-Zhejiang Medicine to pay annual cash div as 1.45 yuan per 10 shares for FY 2016

* Says it plans to pay annual cash dividend as 1.45 yuan(pre-tax) per 10 shares as FY 2016 div payment

BRIEF-Kaneka wins lawsuit regarding patent infringement in US

* Says the co won the lawsuit against Zhejiang Medicine Co. Ltd and ZMC-USA, LLC.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up